A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Latest Information Update: 18 Jul 2024
At a glance
- Drugs Parsaclisib (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms CITADEL-203
- Sponsors Incyte Corporation
- 08 Jul 2024 This trial has been completed in Sweden, according to European Clinical Trials Database record.
- 05 Jul 2024 This trial has been completed in Czechia, according to European Clinical Trials Database record.
- 27 Jun 2024 Status changed from active, no longer recruiting to completed.